Thursday, September 25 | |
---|---|
MTE Sessions | |
18:30 | Welcome Reception |
Friday, September 26 | |
---|---|
08:15-08:30 | Good Morning Coffee |
08:30-08:45 | Welcome Note Congress Co-Chairs |
08:45-10:15 | Session 1 |
Controversy: Is survival prolonged if we used CAR-T in second-line rather than third-line treatment? |
|
Moderator: | |
08:45-09:00 | Yes: Anna Sureda, Spain |
09:00-09:15 | No: |
Controversy: Is Flu/Cy still the best lymphodepleting regimen? |
|
Moderator: Anna Sureda, Spain | |
09:15-09:30 | Yes: |
09:30-09:45 | No: |
09:45-10:15 | Panel discussion: All session faculty |
10:15-10:35 | Coffee Break, Poster Viewing and Visit Exhibition |
10:35-12:05 | Session 2 |
Controversy: Shall we include venetoclax in the induction chemotherapy and/or conditioning regimen before the transplant? | |
Moderator: TBA | |
10:35-10:50 | Yes: Thomas Schroeder, Germany |
10:50-11:05 | No: Jurjen Versluis, Netherlands |
Controversy: Should we transplant TP53 multi-hit AML or MDS? | |
Moderator: Mutlu Arat, Turkey | |
11:05-11:20 | Yes: Coleman Lindsley, USA |
11:20-11:35 | No: Avichai Shimoni, Israel |
11:35-12:05 | Panel discussion: All session faculty |
12:05-12:15 | Technical Break |
12:15-13:15 | Session 3 |
Controversy: TBA | |
Moderator: | |
Yes: | |
No: | |
Controversy: TBA | |
Moderator: | |
Yes: | |
No: | |
Panel discussion: All session faculty | |
13:15-13:45 | Lunch Break, Poster Viewing and Visit Exhibition |
13:45-14:45 | Industry-supported Lunch Symposium |
14:45-15:00 | Short Break |
15:00-16:30 | Session 4 |
Controversy: Is there a future for CAR-T cell therapy in T-All? | |
Moderator: | |
15:00-15:15 | Yes: He Huang, China |
15:15-15:30 | No: Sebastian Giebel, Poland |
Controversy: Are we ready for CAR-T in first-line therapy for MM? | |
Moderator: Nico Gagelmann, Germany | |
15:30-15:45 | Yes: Maximilian Merz, Germany |
15:45-16:00 | No: |
16:00-16:30 | Panel discussion: All session faculty |
16:30-17:00 | Coffee Break, Poster Viewing and Visit Exhibition |
17:00-18:30 | Session 5 |
Controversy: Does MRD before allo impact the outcome for MDS? | |
Moderator: Ibrahim Yakoub-Agha, France | |
17:00-17:15 | Yes: Carmelo Gurnari, Italy |
17:15-17:30 | No: Arjan van de Loosdrecht, Netherlands |
Controversy: Is venetoclax the new partner for 5-Aza in MDS? | |
Moderator: Arjan van de Loosdrecht, Netherlands | |
17:30-17:45 | Yes: Valeria Santini, Italy |
17:45-18:00 | No: Moshe Mittelman, Israel |
18:00-18:30 | Panel discussion: All session faculty |
Saturday, September 27 | |
---|---|
08:30-10:00 | Session 6 |
Controversy: Is there a future for immunotherapy in AML outside allogeneic SCT? | |
Moderator: Charles Craddock, UK | |
08:30-08:45 | Yes: |
08:45-09:00 | No: |
Controversy: Is there a future for academic CARs? | |
Moderator: Valentín Ortíz-Maldonado, Spain | |
09:00-09:15 | Yes: Arnon Nagler, Israel |
09:15-09:30 | No: |
09:30-10:00 | Panel discussion: All session faculty |
10:00-10:20 | Coffee Break, Poster Viewing and Visit Exhibition |
10:20-11:20 | Industry-supported Symposium |
11:20-11:30 | Technical Break |
11:30-13:00 | Session 7 |
Controversy: Is PTCy or ATG-based prophylaxis the better haplo approach in AML? | |
Moderator: Nicolaus Kröger, Germany | |
11:30-11:45 | ATG/ATLG: Xiaojun Huang, China |
11:45-12:00 | PTCy: Leo Luznik, USA |
Controversy: Does HLA matter in HSCT with PTCy? | |
Moderator: Arnon Nagler, Israel | |
12:00-12:15 | Yes: Katharina Fleischhauer, Germany |
12:15-12:30 | No: Fabio Ciceri Italy |
12:30-13:00 | Panel discussion: All session faculty |
13:00-13:30 | Lunch Break, Poster Viewing and Visit Exhibition |
13:30-14:30 | Industry-supported Lunch Symposium |
14:30-14:40 | Technical Break |
14:40-16:10 | Session 8 |
Controversy: Splenectomy vs spleen irradiation in JAKi resistant MPN patients prior to alloSCT | |
Moderator: Donal McLornan, UK | |
14:40-14:55 | Pro splenectomy: Nicola Polverelli, Italy |
14:55-15:10 | Pro spleen irradiation: Nico Gagelmann, Germany |
Controversy: Does cord blood provide a stronger GVL effect than MUD? |
|
Moderator: Robert Soiffer, USA | |
15:10-15:25 | Yes: Robert Wynn, UK |
15:25-15:40 | |
15:40-16:10 | Panel discussion: All session faculty |
16:10-16:20 | Short Break |
16:20-17:50 | Session 9 |
Controversy: Can modulation of microbiome by diet prevent or treat GvHD? | |
Moderator: Ernst Holler, Germany | |
16:20-16:35 | Yes: Marcel van den Brink, USA |
16:35-16:50 | No: |
Controversy: Is fecal transplant the future treatment of SR-GvHD? | |
Moderator: Marcel van den Brink, USA | |
16:50-17:05 | Yes: Ernst Holler, Germany |
17:05-17:20 | No: Pavan Reddy, USA |
17:20-17:50 | Panel discussion: All session faculty |
17:50-18:10 | Coffee Break, Poster Viewing and Visit Exhibition |
18:10-19:30 | Session 10 |
Controversy: Is there a role for combining JAKi with other agents in acute and chronic GvHD? | |
Moderator: Francesca Bonifazi, Italy | |
18:10-18:25 | Yes: |
18:25-18:40 | No: Olaf Penack, Germanyaaa |
Controversy: Are MAGIC criteria and biomarker the standard for classifying and treating acute GvHD? |
|
Moderator: | |
18:40-18:55 | Yes: James Ferrara, USA |
18:55-19:10 | No: Amin Alousi, USA |
19:10-19:30 | Panel discussion: All session faculty |
19:30 | Poster Walk and Awards Session (Poster Area) |
Sunday, September 28 | |
---|---|
09:00-10:30 | Session 11 |
Controversy: Can modern technology (e.g. AI) of large registries replace projective phase III studies? |
|
Moderator: Nicolaus Kröger, Germany | |
09:00-09:15 | Yes: Marcelo Pasquini, USA |
09:15-09:30 | No: Charles Craddock, UK |
Controversy: Can we expect CAR-T cells to treat GvHD? |
|
Moderator: Marcelo Pasquini, USA | |
09:30-09:45 | Yes: Chiara Bonini, Italy |
09:45-10:00 | No: Bruce Blazar, USA |
10:00-10:30 | Panel discussion: All session faculty |
10:30-11:00 | Coffee Break |
11:00-12:30 | Session 12 |
Controversy: CAR-T vs BITE in autoimmune disease |
|
Moderator: Raffaella Greco, Italy | |
11:00-11:15 | Pro CAR: |
11:15-11:30 | Pro BITE: Tobias Alexander, Germany |
Controversy: CAR-T vs BITE in advanced follicular lymphoma |
|
Moderator: | |
11:30-11:45 | Pro CAR: |
11:45-12:00 | Pro BITE: Anna Sureda, Spain |
12:00-12:30 | Panel discussion: All session faculty |
12:30 | Closing Remarks Congress Co-Chairs |